Thiola 100 MG
Ended Awarded
- Contract number
- 36C24526N0130
- Awardee
-
Travere Therapeutics, Inc. UEI JUBZMHK84S36
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $28,975
Award facts
- Contract value 100% obligated
- $28,975.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92130, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs' Veterans Integrated Service Network 5 (VISN 5) awarded a $28,975.20 delivery order to Travere Therapeutics, Inc. for the supply of Thiola 100 mg, a specialized pharmaceutical used to treat cystinuria and related kidney disorders. This award, issued on November 5, 2025, with an ultimate completion date of November 7, 2025, represents a firm fixed-price delivery order issued under Travere's existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract was awarded without set-aside designation through competitive procurement, reflecting the open competition process typical of GSA schedule ordering. The place of performance is San Diego, California, where Travere Therapeutics maintains its headquarters.
This delivery order is issued under Travere Therapeutics' broader Indefinite Delivery Vehicle (IDV) framework with the VA, which includes a Federal Supply Schedule contract valued at approximately $14.97 million expiring in September 2026, as well as Blanket Purchase Agreements totaling $50 million for specialized pharmaceuticals including Thiola and Cholbam. These IDVs enable VISN 5 and other VA networks to efficiently procure rare disease medications under pre-negotiated terms, supporting the agency's mission to provide comprehensive healthcare services to the veteran population. Travere Therapeutics' consistent performance as a supplier of specialized biopharmaceuticals to the VA demonstrates the company's critical role in providing access to treatments for complex medical conditions affecting veterans.
Quick answers
Who was awarded contract 36C24526N0130?
36C24526N0130 was awarded to Travere Therapeutics, Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on November 5, 2025.
How much is contract 36C24526N0130 worth?
The government has obligated $28,975 on 36C24526N0130.
Is contract 36C24526N0130 an order under another contract?
Yes. 36C24526N0130 is a delivery order under 36F79721D0239, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0130 competed?
The extent of competition for 36C24526N0130 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award